Hospital-wide modification of fluoroquinolone policy and meticillin-resistant Staphylococcus aureus rates: A 10-year interrupted time-series analysis

Journal of Hospital Infection

Volumn 78, Issue 2, 2011, Pages 118-122

  Parienti, J J ^a   Cattoir, V ^a   Thibon, P ^a   Lebouvier, G ^a   Verdon, R ^a   Daubin, C ^a   du Cheyron, D ^a   Leclercq, R ^a   Charbonneau, P ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Antibiotic stewardship; Fluoroquinolones; Meticillin resistant Staphylococcus aureus; Time series

Indexed keywords

ALCOHOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE ASSOCIATION; HEALTH CARE POLICY; HOSPITAL HYGIENE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; TIME SERIES ANALYSIS;

ALCOHOLS; ANTI-BACTERIAL AGENTS; CROSS INFECTION; FLUOROQUINOLONES; HANDWASHING; HEALTH POLICY; HOSPITALS, UNIVERSITY; HUMANS; INFECTION CONTROL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS;

EID: 79955949847     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhin.2011.03.008     Document Type: Article

References (19)

1. Linder J.A., Huang E.S., Steinman M.A., Gonzales R., Stafford R.S. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005, 118:259-268.
2. Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., Quinn J.P. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003, 289:885-888.
3. Glass S.K., Pearl D.L., McEwen S.A., Finley R. A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06). J Antimicrob Chemother 2010, 65:2019-2027.
4. Lautenbach E., Larosa L.A., Kasbekar N., Peng H.P., Maniglia R.J., Fishman N.O. Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med 2003, 163:601-605.
5. Charbonneau P., Parienti J.J., Thibon P., et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study. Clin Infect Dis 2006, 42:778-784.
6. Wagner A.K., Soumerai S.B., Zhang F., Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002, 27:299-309.
7. Aubry-Damon H., Legrand P., Brun-Buisson C., Astier A., Soussy C.J., Leclercq R. Reemergence of gentamicin-susceptible strains of methicillin-resistant Staphylococcus aureus: roles of an infection control program and changes in aminoglycoside use. Clin Infect Dis 1997, 25:647-653.
8. Pittet D., Hugonnet S., Harbarth S., et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet 2000, 356:1307-1312.
9. MacDougall C., Powell J.P., Johnson C.K., Edmond M.B., Polk R.E. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005, 41:435-440.
10. Harbarth S., Liassine N., Dharan S., Herrault P., Auckenthaler R., Pittet D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000, 31:1380-1385.
11. Weber S.G., Gold H.S., Hooper D.C., Karchmer A.W., Carmeli Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003, 9:1415-1422.
12. Rangaraj G., Granwehr B.P., Jiang Y., Hachem R., Raad I. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 2010, 116:967-973.
13. Monnet D.L., MacKenzie F.M., Lopez-Lozano J.M., et al. Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000. Emerg Infect Dis 2004, 10:1432-1441.
14. Bosso J.A., Mauldin P.D. Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:2106-2112.
15. Aldeyab M.A., Monnet D.L., Lopez-Lozano J.M., et al. Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus: a time-series analysis. J Antimicrob Chemother 2008, 62:593-600.
16. Liebowitz L.D., Blunt M.C. Modification in prescribing practices for third-generation cephalosporins and ciprofloxacin is associated with a reduction in meticillin-resistant Staphylococcus aureus bacteraemia rate. J Hosp Infect 2008, 69:328-336.
17. Hota B. Infection control or formulary control: what is the best tool to reduce nosocomial infections due to methicillin-resistant Staphylococcus aureus?. Clin Infect Dis 2006, 42:785-787.
18. Rahal J.J., Urban C., Horn D., et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998, 280:1233-1237.
19. Vernaz N., Sax H., Pittet D., Bonnabry P., Schrenzel J., Harbarth S. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and Clostridium difficile. J Antimicrob Chemother 2008, 62:601-607.